drugset / Trial / NCT04272775
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor activity of ixazomib in participants with RRMM.
Timeline
- Start
- 2012-06-05
- Primary completion
- 2019-02-15
- Completion
- 2019-02-15
Outcome
Outcome not reported
Stopped (Business): “Business Decision; No Safety Or Efficacy Concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Subject | Ixazomib | Unknown | 5.5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |